Alto Neuroscience (Alto Neuroscience) Cash And Cash Equivalents : $205.90 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience Cash And Cash Equivalents?

Alto Neuroscience's quarterly cash and cash equivalents increased from Sep. 2023 ($51.29 Mil) to Dec. 2023 ($82.55 Mil) and increased from Dec. 2023 ($82.55 Mil) to Mar. 2024 ($205.90 Mil).

Alto Neuroscience's annual cash and cash equivalents increased from Dec. 2021 ($25.71 Mil) to Dec. 2022 ($48.34 Mil) and increased from Dec. 2022 ($48.34 Mil) to Dec. 2023 ($82.55 Mil).

Alto Neuroscience Cash And Cash Equivalents Historical Data

The historical data trend for Alto Neuroscience's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience Cash And Cash Equivalents Chart

Alto Neuroscience Annual Data

Trend

Dec21

Dec22

Dec23

Cash And Cash Equivalents

25.71

48.34

82.55

Alto Neuroscience Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial			48.34	-	51.29	82.55	205.90

Alto Neuroscience Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Alto Neuroscience (NYSE:ANRO) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Alto Neuroscience Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Alto Neuroscience's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Alto Neuroscience (Alto Neuroscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Alto Neuroscience Inc is a clinical stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective treatment options. the company currently consists of five clinical-stage assets initially targeting major depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience (Alto Neuroscience) Headlines

From GuruFocus

Steven Cohen's Point72 Asset Management Buys New Stake in Alto Neuroscience Inc

By GuruFocus Research • 02-08-2024